Cai S, Hu T, Venkatesan M, Allam M, Schneider F, Ramalingam S, et al. Multiplexed protein profiling reveals spatial subcellular signaling networks. iScience. 2022;25:104980 pubmed publisher

Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, et al. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol Cell. 2021;: pubmed publisher

Zhu Y, Shi C, Bruins L, Wang X, Riggs D, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9:19 pubmed publisher

Eichner R, Heider M, Fernández Sáiz V, van Bebber F, Garz A, Lemeer S, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016;22:735-43 pubmed publisher

Bhat N, Adams C, Chen Y, Bieber M, Teng N. Identification of Cell Surface Straight Chain Poly-N-Acetyl-Lactosamine Bearing Protein Ligands for VH4-34-Encoded Natural IgM Antibodies. J Immunol. 2015;195:5178-88 pubmed publisher

Hemdan T, Malmström P, Jahnson S, Segersten U. Emmprin Expression Predicts Response and Survival following Cisplatin Containing Chemotherapy for Bladder Cancer: A Validation Study. J Urol. 2015;194:1575-81 pubmed publisher

Giebel N, de Jaime Soguero A, García Del Arco A, Landry J, Tietje M, Villacorta L, et al. USP42 protects ZNRF3/RNF43 from R-spondin-dependent clearance and inhibits Wnt signalling. EMBO Rep. 2021;22:e51415 pubmed publisher

Voss D, Spina R, Carter D, Lim K, Jeffery C, Bar E. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017;7:4292 pubmed publisher

Kendrick A, Schafer J, Dzieciatkowska M, Nemkov T, D Alessandro A, Neelakantan D, et al. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget. 2017;8:6742-6762 pubmed publisher

To M, Peterson C, Roberts M, Counihan J, Wu T, Forster M, et al. Lipid disequilibrium disrupts ER proteostasis by impairing ERAD substrate glycan trimming and dislocation. Mol Biol Cell. 2017;28:270-284 pubmed publisher

El Rehim D, El Maqsoud N, El Hamid A, El Bab T, Galal E. Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics. Mol Clin Oncol. 2013;1:297-304 pubmed

Tian L, Zhang Y, Chen Y, Cai M, Dong H, Xiong L. EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. PLoS ONE. 2013;8:e58069 pubmed publisher

Bi X, Liu J, He H, Ye Y, Han Z, Dai Q, et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol. 2012;14:190-6 pubmed

Du Z, Hu C, Shao Q, Huang M, Kou C, Zhu X, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009;125:1832-41 pubmed publisher

Umar A, Kang H, Timmermans A, Look M, Meijer van Gelder M, Den Bakker M, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics. 2009;8:1278-94 pubmed publisher

Sillanpää S, Anttila M, Suhonen K, Hamalainen K, Turpeenniemi Hujanen T, Puistola U, et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol. 2007;28:280-9 pubmed

Als A, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13:4407-14 pubmed